Investor Relations

Company Overview

Lexaria Bioscience Corp. (CSE:LXX; NASDAQ:LEXX) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes faster delivery of drugs into the bloodstream, healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s DehydraTECH technology is covered by issued and pending patents in over 40 countries around the world. Lexaria’s first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. Lexaria has filed for patent protection for delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors, tobacco and more.

In 2020, Lexaria’s most urgent investigations are related to applying DehydraTECH to existing antiviral and other drugs that may be useful in the fight against Coronavirus.

Lexaria’s technology has been thoroughly evaluated through in vivo, in vitro, and human clinical testing.Liquid chromatography high-resolution mass spectrometry, nuclear magnetic resonance, Fourier transform infrared (“FTIR”) spectroscopy and other evaluatory processes have been used to characterize and study the transformative Lexaria technology.